EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...
The University of Copenhagen scientists — funded by Ozempic maker Novo Nordisk — wanted to see if they could create ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback